ReShape Lifesciences Inc. (RSLS)
NASDAQ: RSLS · Real-Time Price · USD
0.3650
-0.0150 (-3.95%)
At close: Apr 25, 2025, 4:00 PM
0.3614
-0.0036 (-0.99%)
After-hours: Apr 25, 2025, 7:27 PM EDT
ReShape Lifesciences Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for ReShape Lifesciences.
Analyst Consensus: Hold
Analyst Ratings
According to 1 stock analyst, the rating for ReShape Lifesciences is "Hold". This means that the analyst believes this stock is likely to perform similarly to the overall market.
Recommendation Trends
Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
---|---|---|---|---|
Strong Buy | 0 | 0 | 0 | 0 |
Buy | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 |
Total | 1 | 1 | 1 | 1 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Maxim Group | Maxim Group | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Jul 17, 2024 |
Alliance Global Partners | Alliance Global Partners | Strong Buy Maintains $15,950 → $13,485 | Strong Buy | Maintains | $15,950 → $13,485 | +3,694,420.55% | May 26, 2022 |
Maxim Group | Maxim Group | Strong Buy Initiates $23,200 | Strong Buy | Initiates | $23,200 | +6,356,064.38% | Oct 8, 2021 |
Financial Forecast
Revenue This Year
12.23M
from 8.01M
Increased by 52.80%
Revenue Next Year
n/a
from 12.23M
EPS This Year
-0.37
from -13.83
EPS Next Year
n/a
from -0.37
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 |
---|---|
High | 12.6M |
Avg | 12.2M |
Low | 11.8M |
Revenue Growth
Revenue Growth | 2025 |
---|---|
High | 57.3% |
Avg | 52.8% |
Low | 46.8% |
EPS Forecast
EPS | 2025 |
---|---|
High | -0.38 |
Avg | -0.37 |
Low | -0.35 |
EPS Growth
EPS Growth | 2025 |
---|---|
High | - |
Avg | - |
Low | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.